COMPAZINE
LOE ApproachingNDAORALSYRUP
Approved
Dec 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is an oral syrup small-molecule antipsychotic and antiemetic approved in 1957. The drug is primarily used for nausea, vomiting, and psychiatric conditions. It works as a dopamine antagonist in the central nervous system.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting defensive positioning and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COMPAZINE roles focus on defensive commercial management and generic transition strategy rather than growth. Career opportunities are limited and primarily suited for professionals experienced in legacy product management and competitive erosion mitigation.
Brand ManagerField Sales Representative
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.